T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

Cancer imaging company Kuva Labs is expanding its scope via the acquisition of solid tumor biotech Lisata Therapeutics.

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Only four months after IO Biotech decided to halve its head count, the Danish biotech is already considering whether it must ...

Artificial-intelligence-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibi | ...

For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union ...

Worldwide Clinical Trials is expanding its horizons with the acquisition of Catalyst Clinical Research, a specialist oncology ...

Two former executives from Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allege | ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...